BioElectronics' OTC ActiPatch? Musculoskeletal Pain Therapy Clinically Proven to Reduce Osteoarthritis Pain and Disability - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
BioElectronics' OTC ActiPatch? Musculoskeletal Pain Therapy Clinically Proven to Reduce Osteoarthritis Pain and Disability


BioElectronics' OTC ActiPatch® Musculoskeletal Pain Therapy Clinically Proven to Reduce Osteoarthritis Pain and Disability

PR Newswire

FREDERICK, Md., May 14, 2014 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today announced more detail on the interim results of a randomized, double blind, placebo controlled trial on osteoarthritis of the knee (knee pain) using ActiPatch® Therapy.  The interim results are now published online at the EULAR (European League against Arthritis) conference website at https://b-com.mci-group.com/AbstractList/EULAR2014.aspx and search for abstract #: AB0777.

"Arthritis is the major cause of disability in the US affecting 52.5 million adults. Osteoarthritis of the knee is the most common musculoskeletal pain and disability condition. Therefore we are extremely pleased by the results of Dr. Gianluca Bagnato's clinical study," commented Ian Rawe, Ph.D. Director of Research, BioElectronics.  Dr. Rawe noted that the study looked at three important measures associated with Osteoarthritis, these being pain, ease of movement and overall patient quality of life. "Importantly the study results show significant improvement in all three measures for the group wearing the active ActiPatch device relative to the group wearing the non-active device. We take these results as strong support for our contention that our affordable innovative drug-free technology can greatly reduce disabilities, physician office visits, and the reliance on drugs for chronic pain."

ActiPatch® Musculoskeletal Pain Therapy devices are readily available, over-the-counter outside of the US, for approximately $30.00, or $0.04 per hour of therapy.

The specific four weeks of ActiPatch® Therapy showed the following:

  • Patients treated with ActiPatch® Therapy showed a statistically significant improvement in visual analogue pain scores (VAS) (p<0.005) and WOMAC* pain scores (p<0.001) at 4 weeks compared to baseline.
  • Patients treated with ActiPatch® Therapy assessed for function and disability showed statistically significant improvement for WOMAC* function (p<0.002) and WOMAC* stiffness (p<0.02) at 4 weeks compared to baseline.
  • Patients treated with ActiPatch® Therapy also demonstrated statistically significant (p<0.04) improved physical and mental health as assessed by the SF-36 (36-item Medical Outcomes Study Short-Form 36 version 2) at 4 weeks compared to baseline.
  • No statistically significant results were recorded in the placebo group.

[*WOMAC - Western Ontario and McMaster Universities Osteoarthritis Index]

Other Clinical Research

BioElectronics is conducting a series of clinical research studies using its medical devices. Details can be found at http://www.bielcorp.com/clinical-evidence/ along with details of previously completed and published clinical trials. 

About BioElectronics Corporation

BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, anti-inflammatory devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses.  For more information, please visit www.bielcorp.com.

Contact:
Paul Knopick
940.262.3584
pknopick@eandecommunications.com   

 

SOURCE BioElectronics Corporation

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here